Replies to post #149071 on Biotech Values

[Icebreaker]

"Bristol's PD-1 program is certainly pretty exciting in the oncology space."

I realize it is a long shot, but it seems to me that Pfizer must be thinking about taking out Bristol. They would gain 100% of Eliquis and they would gain maybe the best asset in oncology Anti PD-1.